Sionna Therapeutics presents plans for Phase 2 trial of cystic fibrosis drug combination
SION•Sionna Therapeutics expects to start its AscenSION CF Phase 2 trial of SION-451 and SION-2222 in the first quarter of 2027. The company reported approximately $250 million in cash at the end of the third quarter of 2026, with runway into the second half of 2029.
1. Trial plans
Sionna Therapeutics expects to initiate its open-label AscenSION CF Phase 2 proof-of-concept trial in the first quarter of 2027. The 28-day study will evaluate SION-451 and SION-2222 in cystic fibrosis patients switching from Trikafta.
2. Phase 1 and cash
The company said Phase 1 testing met safety and tolerability objectives, with drug exposure exceeding targets in the selected dose range. Cash totaled approximately $250 million at the end of the third quarter of 2026, and Sionna expects it to fund AscenSION CF and subsequent development into the second half of 2029.
